LU92513I2 - Sofosbuvir et ses dérivés pharmaceutiquement acceptables (solvaldi) - Google Patents
Sofosbuvir et ses dérivés pharmaceutiquement acceptables (solvaldi) Download PDFInfo
- Publication number
- LU92513I2 LU92513I2 LU92513C LU92513C LU92513I2 LU 92513 I2 LU92513 I2 LU 92513I2 LU 92513 C LU92513 C LU 92513C LU 92513 C LU92513 C LU 92513C LU 92513 I2 LU92513 I2 LU 92513I2
- Authority
- LU
- Luxembourg
- Prior art keywords
- solvaldi
- sofosbuvir
- pharmaceutically acceptable
- acceptable derivatives
- derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
- C07K9/001—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence having less than 12 amino acids and not being part of a ring structure
- C07K9/003—Peptides being substituted by heterocyclic radicals, e.g. bleomycin, phleomycin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/067—Pyrimidine radicals with ribosyl as the saccharide radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US39235102P | 2002-06-28 | 2002-06-28 | |
US46619403P | 2003-04-28 | 2003-04-28 | |
US47094903P | 2003-05-14 | 2003-05-14 | |
PCT/US2003/020431 WO2004002422A2 (fr) | 2002-06-28 | 2003-06-27 | Ester 3'-l-valine de ?-d-2'-c-methyl-ribofuranosyl cytidine pour le traitement d'infections par des flaviviridae |
Publications (1)
Publication Number | Publication Date |
---|---|
LU92513I2 true LU92513I2 (fr) | 2015-11-02 |
Family
ID=30003834
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
LU92513C LU92513I2 (fr) | 2002-06-28 | 2014-08-07 | Sofosbuvir et ses dérivés pharmaceutiquement acceptables (solvaldi) |
Country Status (16)
Country | Link |
---|---|
US (9) | US7456155B2 (fr) |
EP (1) | EP1536804A4 (fr) |
JP (1) | JP2005533824A (fr) |
KR (1) | KR20050035194A (fr) |
CN (1) | CN1678326A (fr) |
AP (1) | AP2005003213A0 (fr) |
AU (1) | AU2003248748A1 (fr) |
BR (1) | BR0312278A (fr) |
CA (1) | CA2489552A1 (fr) |
LU (1) | LU92513I2 (fr) |
MA (1) | MA27374A1 (fr) |
MX (1) | MXPA04012802A (fr) |
NO (1) | NO20050490L (fr) |
PL (1) | PL374781A1 (fr) |
RS (1) | RS113904A (fr) |
WO (1) | WO2004002422A2 (fr) |
Families Citing this family (188)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY164523A (en) * | 2000-05-23 | 2017-12-29 | Univ Degli Studi Cagliari | Methods and compositions for treating hepatitis c virus |
JP5230052B2 (ja) * | 2000-05-26 | 2013-07-10 | イデニクス(ケイマン)リミテツド | フラビウイルスおよびペスチウイルス治療のための方法および組成物 |
US6875751B2 (en) * | 2000-06-15 | 2005-04-05 | Idenix Pharmaceuticals, Inc. | 3′-prodrugs of 2′-deoxy-β-L-nucleosides |
WO2004002422A2 (fr) * | 2002-06-28 | 2004-01-08 | Idenix (Cayman) Limited | Ester 3'-l-valine de ?-d-2'-c-methyl-ribofuranosyl cytidine pour le traitement d'infections par des flaviviridae |
NZ537662A (en) * | 2002-06-28 | 2007-10-26 | Idenix Cayman Ltd | 2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections |
US7608600B2 (en) * | 2002-06-28 | 2009-10-27 | Idenix Pharmaceuticals, Inc. | Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections |
US7323449B2 (en) | 2002-07-24 | 2008-01-29 | Merck & Co., Inc. | Thionucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase |
US7094768B2 (en) * | 2002-09-30 | 2006-08-22 | Genelabs Technologies, Inc. | Nucleoside derivatives for treating hepatitis C virus infection |
WO2004028481A2 (fr) | 2002-09-30 | 2004-04-08 | Genelabs Technologies, Inc. | Derives nucleosidiques servant au traitement d'une infection par le virus de l'hepatite c |
WO2004041837A1 (fr) | 2002-10-31 | 2004-05-21 | Metabasis Therapeutics, Inc. | Nouveaux promedicaments de cytarabine monophosphate |
CA2506129C (fr) * | 2002-11-15 | 2015-02-17 | Idenix (Cayman) Limited | Nucleoside a ramification en 2' et mutation de flaviviridae |
AU2003300901A1 (en) * | 2002-12-12 | 2004-06-30 | Idenix (Cayman) Limited | Process for the production of 2'-branched nucleosides |
NZ540913A (en) * | 2002-12-23 | 2008-02-29 | Idenix Cayman Ltd | Process for the production of 3'-nucleoside prodrugs |
AU2004224575A1 (en) * | 2003-03-28 | 2004-10-07 | Pharmasset Ltd. | Compounds for the treatment of flaviviridae infections |
WO2005003147A2 (fr) | 2003-05-30 | 2005-01-13 | Pharmasset, Inc. | Analogues de nucleosides fluores modifies |
WO2005009418A2 (fr) * | 2003-07-25 | 2005-02-03 | Idenix (Cayman) Limited | Analogues des nucleosides puriques pour traiter flaviviridae et notamment l'hepatite c |
WO2005018330A1 (fr) * | 2003-08-18 | 2005-03-03 | Pharmasset, Inc. | Regime de dosage pour therapie contre flaviviridae |
GB0320638D0 (en) | 2003-09-03 | 2003-10-01 | Novartis Ag | Organic compounds |
GB0500020D0 (en) | 2005-01-04 | 2005-02-09 | Novartis Ag | Organic compounds |
US20050182252A1 (en) | 2004-02-13 | 2005-08-18 | Reddy K. R. | Novel 2'-C-methyl nucleoside derivatives |
TWI368507B (en) | 2004-02-20 | 2012-07-21 | Boehringer Ingelheim Int | Viral polymerase inhibitors |
WO2005094897A2 (fr) * | 2004-04-01 | 2005-10-13 | Cardiome Pharma Corp. | Derives de composes de modulation des canaux ioniques, compositions pharmaceutiques et utilisations |
AU2005254057B2 (en) | 2004-06-15 | 2011-02-17 | Isis Pharmaceuticals, Inc. | C-purine nucleoside analogs as inhibitors of RNA-dependent RNA viral polymerase |
AU2005256963A1 (en) * | 2004-06-23 | 2006-01-05 | Centre National De La Recherche Scientifique | 5-aza-7-deazapurine derivatives for treating infections with flaviviridae |
CN101023094B (zh) | 2004-07-21 | 2011-05-18 | 法莫赛特股份有限公司 | 烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备 |
EP1795206A4 (fr) | 2004-08-11 | 2009-07-22 | Chugai Pharmaceutical Co Ltd | Medicament pour le traitement du vhc ou la prevention de l'infection par vhc |
SI3109244T1 (sl) | 2004-09-14 | 2019-06-28 | Gilead Pharmasset Llc | Priprava 2'fluoro-2'-alkil-substituiranih ali drugih neobvezno substituiranih ribofuranozil pirimidinov in purinov in njihovih derivatov |
RU2007115419A (ru) * | 2004-09-24 | 2008-10-27 | Айденикс (Кайман) Лимитед (Ky) | Способы и композиции для лечения флавивирусов, пестивирусов и гепацивируса |
NZ555143A (en) * | 2004-12-23 | 2009-12-24 | Novartis Ag | Compositions for HCV treatment |
US7524831B2 (en) | 2005-03-02 | 2009-04-28 | Schering Corporation | Treatments for Flaviviridae virus infection |
GT200600119A (es) * | 2005-03-24 | 2006-10-25 | Composiciones farmaceuticas | |
WO2006137953A1 (fr) | 2005-04-01 | 2006-12-28 | The Regents Of The Univerisity Of California | Nucleosides phosphono-pent-2-en-1-yle et analogues |
US20090156545A1 (en) * | 2005-04-01 | 2009-06-18 | Hostetler Karl Y | Substituted Phosphate Esters of Nucleoside Phosphonates |
CA2606195C (fr) | 2005-05-02 | 2015-03-31 | Merck And Co., Inc. | Inhibiteurs de la protease ns3 du vhc |
AU2006259348B2 (en) | 2005-06-17 | 2010-07-22 | Novartis Ag | Use of sanglifehrin in HCV |
AR057456A1 (es) | 2005-07-20 | 2007-12-05 | Merck & Co Inc | Inhibidores de la proteasa ns3 del vhc |
BRPI0614205A2 (pt) | 2005-08-01 | 2016-11-22 | Merck & Co Inc | composto, composição farmacêutica, e, uso de composto |
US20070185063A1 (en) * | 2005-08-23 | 2007-08-09 | Idenix Pharmaceuticals, Inc. | Seven-membered ring nucleosides |
NZ567262A (en) * | 2005-09-30 | 2011-12-22 | Scynexis Inc | Cyclosporin derivatives and their use for the treatment and prevention of hepatitis C infection |
US8329658B2 (en) * | 2005-09-30 | 2012-12-11 | Scynexis, Inc. | Arylalkyl and heteroarylalkyl derivatives of cyclosporine A for the treatment and prevention of viral infection |
UA91255C2 (uk) | 2005-12-09 | 2010-07-12 | Ф. Хоффманн-Ля Рош Аг | Антивірусні нуклеозиди |
WO2007075876A2 (fr) * | 2005-12-23 | 2007-07-05 | Idenix Pharmaceuticals, Inc. | Procede pour la preparation d’un intermediaire synthetique pour la preparation de nucleosides ramifies |
US8895531B2 (en) | 2006-03-23 | 2014-11-25 | Rfs Pharma Llc | 2′-fluoronucleoside phosphonates as antiviral agents |
WO2007113159A1 (fr) | 2006-04-04 | 2007-10-11 | F. Hoffmann-La Roche Ag | Nucléosides 3',5'-di-o-acylés destinés au traitement du vhc |
RU2448976C2 (ru) | 2006-04-11 | 2012-04-27 | Новартис Аг | Ингибиторы hcv/вич и их применение |
GB0609492D0 (en) | 2006-05-15 | 2006-06-21 | Angeletti P Ist Richerche Bio | Therapeutic agents |
KR20090021163A (ko) * | 2006-05-16 | 2009-02-27 | 도쿄 메트로폴리탄 오거니제이션 포 메디칼 리서치 | Hcv 감염증을 치료 또는 예방하기 위한 의약 조성물 |
US8058260B2 (en) * | 2006-05-22 | 2011-11-15 | Xenoport, Inc. | 2′-C-methyl-ribofuranosyl cytidine prodrugs, pharmaceutical compositions and uses thereof |
GB0612423D0 (en) | 2006-06-23 | 2006-08-02 | Angeletti P Ist Richerche Bio | Therapeutic agents |
US20080182895A1 (en) * | 2006-08-25 | 2008-07-31 | Howe Anita Y M | Identification and characterization of hcv replicon variants with reduced susceptibility to hcv-796, and methods related thereto |
WO2008033466A2 (fr) * | 2006-09-14 | 2008-03-20 | Combinatorx (Singapore) Pre. Ltd. | Compositions et procédés pour le traitement de maladies virales |
ES2392948T3 (es) * | 2006-10-10 | 2012-12-17 | Janssen Products, L.P. | Intermedio para inhibidores nucleosídicos de VHC |
JP5252459B2 (ja) * | 2006-10-10 | 2013-07-31 | ギリアド ファーマセット エルエルシー | リボフラノシルピリミジンヌクレオシドの調製 |
CA2667165A1 (fr) | 2006-10-24 | 2008-05-02 | Merck & Co., Inc. | Inhibiteurs de la protease hcv ns3 |
WO2008051514A2 (fr) | 2006-10-24 | 2008-05-02 | Merck & Co., Inc. | Inhibiteurs de la protéase ns3 du hcv |
EP2079479B1 (fr) | 2006-10-24 | 2014-11-26 | Merck Sharp & Dohme Corp. | Inhibiteurs de la protéase ns3 du vhc |
CA2667032A1 (fr) | 2006-10-27 | 2008-05-15 | Merck & Co., Inc. | Inhibiteurs de protease ns3 du vhc |
KR101615500B1 (ko) | 2006-10-27 | 2016-04-27 | 머크 샤프 앤드 돔 코포레이션 | Hcv ns3 프로테아제 억제제 |
JP5084839B2 (ja) | 2006-11-09 | 2012-11-28 | エフ.ホフマン−ラ ロシュ アーゲー | チアゾール及びオキサゾール置換アリールアミド |
US8501933B2 (en) | 2006-11-09 | 2013-08-06 | Roche Palo Alto Llc | Thiazole and oxazole-substituted arylamides as P2X3 and P2X2/3 antagonists |
WO2008069917A2 (fr) | 2006-11-20 | 2008-06-12 | Scynexis, Inc. | Nouveaux peptides cycliques |
JP2010513450A (ja) | 2006-12-20 | 2010-04-30 | イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー | 抗ウイルス性インドール |
GB0625345D0 (en) | 2006-12-20 | 2007-01-31 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
GB0625349D0 (en) | 2006-12-20 | 2007-01-31 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
US7951789B2 (en) | 2006-12-28 | 2011-05-31 | Idenix Pharmaceuticals, Inc. | Compounds and pharmaceutical compositions for the treatment of viral infections |
JP2010515680A (ja) | 2007-01-05 | 2010-05-13 | メルク・シャープ・エンド・ドーム・コーポレイション | Rna依存性rnaウイルス感染症の治療用としてのヌクレオシドアリールホスホロアミデート |
US7964580B2 (en) | 2007-03-30 | 2011-06-21 | Pharmasset, Inc. | Nucleoside phosphoramidate prodrugs |
GB0709791D0 (en) * | 2007-05-22 | 2007-06-27 | Angeletti P Ist Richerche Bio | Antiviral agents |
AU2008277442A1 (en) | 2007-07-17 | 2009-01-22 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa | Macrocyclic indole derivatives for the treatment of hepatitis C infections |
JP5433573B2 (ja) | 2007-07-19 | 2014-03-05 | イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・エルレ・エルレ | 抗ウイルス剤としての大環状化合物 |
US8227431B2 (en) * | 2008-03-17 | 2012-07-24 | Hetero Drugs Limited | Nucleoside derivatives |
TW200946541A (en) | 2008-03-27 | 2009-11-16 | Idenix Pharmaceuticals Inc | Solid forms of an anti-HIV phosphoindole compound |
AU2009241445A1 (en) | 2008-04-28 | 2009-11-05 | Merck Sharp & Dohme Corp. | HCV NS3 protease inhibitors |
WO2010002428A2 (fr) * | 2008-06-06 | 2010-01-07 | Scynexis, Inc. | Nouveaux peptides macrocycliques |
US20090306033A1 (en) * | 2008-06-06 | 2009-12-10 | Keqiang Li | Novel cyclic peptides |
US8173621B2 (en) * | 2008-06-11 | 2012-05-08 | Gilead Pharmasset Llc | Nucleoside cyclicphosphates |
EP2476690A1 (fr) | 2008-07-02 | 2012-07-18 | IDENIX Pharmaceuticals, Inc. | Composés et compositions pharmaceutiques pour le traitement d'infections virales |
ES2491090T3 (es) | 2008-07-22 | 2014-09-05 | Merck Sharp & Dohme Corp. | Combinaciones de un compuesto de quinoxalina macrocíclica que es un inhibidor de la proteasa NS3 del VHC con otros agentes del VHC |
CN102216316A (zh) | 2008-09-05 | 2011-10-12 | 寿制药株式会社 | 取代胺衍生物及以其为有效成分的药物组合物 |
WO2010061881A1 (fr) | 2008-11-26 | 2010-06-03 | 中外製薬株式会社 | Ologoribonucléotide ou acide nucléique de peptide capable d'inhiber l'activité du virus de l'hépatite c |
SG172363A1 (en) | 2008-12-23 | 2011-07-28 | Pharmasset Inc | Synthesis of purine nucleosides |
WO2010075517A2 (fr) | 2008-12-23 | 2010-07-01 | Pharmasset, Inc. | Analogues de nucléoside |
CL2009002207A1 (es) | 2008-12-23 | 2011-02-18 | Gilead Pharmasset Llc | Compuestos derivados de 3-hidroxi-5-(9h-purin-9-il)tetrahidrofuran-2-il, inhibidor de la replicacion de arn viral dependiente de arn; composicion farmaceutica; uso para el tratamiento de hepatitis c. |
JP5780969B2 (ja) | 2008-12-31 | 2015-09-16 | サイネクシス,インコーポレーテッド | シクロスポリンaの誘導体 |
WO2010082050A1 (fr) | 2009-01-16 | 2010-07-22 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Composés benzoxazocines substitués 7-aminoalkyle macrocycycliques destinés au traitement des infections par hépatite c |
GB0900914D0 (en) | 2009-01-20 | 2009-03-04 | Angeletti P Ist Richerche Bio | Antiviral agents |
US8193372B2 (en) | 2009-03-04 | 2012-06-05 | Idenix Pharmaceuticals, Inc. | Phosphothiophene and phosphothiazole HCV polymerase inhibitors |
US20110182850A1 (en) | 2009-04-10 | 2011-07-28 | Trixi Brandl | Organic compounds and their uses |
US8512690B2 (en) | 2009-04-10 | 2013-08-20 | Novartis Ag | Derivatised proline containing peptide compounds as protease inhibitors |
CN101954076A (zh) * | 2009-04-27 | 2011-01-26 | 免疫制剂美国公司 | 自身免疫性肝炎的免疫疗法和预防 |
TWI583692B (zh) | 2009-05-20 | 2017-05-21 | 基利法瑪席特有限責任公司 | 核苷磷醯胺 |
US20100297079A1 (en) * | 2009-05-20 | 2010-11-25 | Chimerix, Inc. | Compounds, compositions and methods for treating viral infection |
US8618076B2 (en) | 2009-05-20 | 2013-12-31 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
SG177308A1 (en) * | 2009-06-22 | 2012-02-28 | Hoffmann La Roche | Novel biphenyl and phenyl-pyridine amides |
SG177301A1 (en) * | 2009-06-22 | 2012-02-28 | Hoffmann La Roche | Novel indole, indazole and benzimidazole arylamides as p2x3 and/or p2x2/3 antagonists |
ES2593405T3 (es) * | 2009-06-22 | 2016-12-09 | F. Hoffmann-La Roche Ag | Nuevas arilamidas sustituidas por benzoxazolona |
US20110020272A1 (en) * | 2009-07-24 | 2011-01-27 | Ulrich Schubert | Combination therapy for treating hepatitis viral infection |
WO2011014487A1 (fr) | 2009-07-30 | 2011-02-03 | Merck Sharp & Dohme Corp. | Inhibiteurs de protéase ns3 du virus de l'hépatite c |
TW201117812A (en) | 2009-08-05 | 2011-06-01 | Idenix Pharmaceuticals Inc | Macrocyclic serine protease inhibitors |
EP2499493A1 (fr) | 2009-11-14 | 2012-09-19 | F. Hoffmann-La Roche AG | Marqueurs biologiques destinés à prédire une réaction rapide au traitement du virus de l'hépatite c (hcv) |
EP2501709A4 (fr) * | 2009-11-16 | 2013-11-13 | Univ Georgia | Nucléosides carbocycliques de type 2'-fluoro-6'-méthylène et méthodes de traitement d'infections virales |
US20110117055A1 (en) | 2009-11-19 | 2011-05-19 | Macdonald James E | Methods of Treating Hepatitis C Virus with Oxoacetamide Compounds |
KR20120085877A (ko) | 2009-12-02 | 2012-08-01 | 에프. 호프만-라 로슈 아게 | Hcv 치료에 대한 지속된 반응을 예측하기 위한 생체마커 |
MX2012006877A (es) | 2009-12-18 | 2012-08-31 | Idenix Pharmaceuticals Inc | Inhibidores de virus de hepatitis c de arileno o heteroarileno 5, 5 - fusionado. |
AP3515A (en) | 2010-03-31 | 2016-01-11 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
US8563530B2 (en) | 2010-03-31 | 2013-10-22 | Gilead Pharmassel LLC | Purine nucleoside phosphoramidate |
WO2011123586A1 (fr) | 2010-04-01 | 2011-10-06 | Idenix Pharmaceuticals, Inc. | Composés et compositions pharmaceutiques pour le traitement d'infections virales |
ES2701020T3 (es) | 2010-09-22 | 2019-02-20 | Alios Biopharma Inc | Nucleósidos azido y análogos nucleotídicos |
CN103209987B (zh) | 2010-09-22 | 2017-06-06 | 艾丽奥斯生物制药有限公司 | 取代的核苷酸类似物 |
EA201390532A1 (ru) | 2010-10-08 | 2013-09-30 | Новартис Аг | Композиции сульфамидых ингибиторов ns3, содержащие витамин е |
JP6069215B2 (ja) | 2010-11-30 | 2017-02-01 | ギリアド ファーマセット エルエルシー | 化合物 |
WO2012080050A1 (fr) | 2010-12-14 | 2012-06-21 | F. Hoffmann-La Roche Ag | Formes solides d'un composé de phénoxybenzènesulfonyle |
WO2012109398A1 (fr) | 2011-02-10 | 2012-08-16 | Idenix Pharmaceuticals, Inc. | Inhibiteurs macrocycliques de sérine protéase, compositions pharmaceutiques les contenant et leur utilisation pour le traitement des infections par le vhc |
US20120252721A1 (en) | 2011-03-31 | 2012-10-04 | Idenix Pharmaceuticals, Inc. | Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor |
EP2691409B1 (fr) | 2011-03-31 | 2018-02-21 | Idenix Pharmaceuticals LLC. | Composés et compositions pharmaceutiques pour le traitement d'infections virales |
CN102775458B (zh) * | 2011-05-09 | 2015-11-25 | 中国人民解放军军事医学科学院毒物药物研究所 | β-D-(2’R)-2’-脱氧—2’-氟-2’-C-甲基胞苷衍生物的制备及用途 |
US9403863B2 (en) | 2011-09-12 | 2016-08-02 | Idenix Pharmaceuticals Llc | Substituted carbonyloxymethylphosphoramidate compounds and pharmaceutical compositions for the treatment of viral infections |
WO2013039855A1 (fr) | 2011-09-12 | 2013-03-21 | Idenix Pharmaceuticals, Inc. | Composés et compositions pharmaceutiques pour le traitement d'infections virales |
UA116087C2 (uk) | 2011-09-16 | 2018-02-12 | Гіліад Фармассет Елелсі | Композиція для лікування вірусу гепатиту c |
EP2768838A1 (fr) | 2011-10-14 | 2014-08-27 | IDENIX Pharmaceuticals, Inc. | Phosphates 3',5'-cycliques substitués de composés nucléotidiques purines et compositions pharmaceutiques pour le traitement d'infections virales |
WO2013074386A2 (fr) | 2011-11-15 | 2013-05-23 | Merck Sharp & Dohme Corp. | Inhibiteurs de la protéase ns3 du vhc |
US8889159B2 (en) | 2011-11-29 | 2014-11-18 | Gilead Pharmasset Llc | Compositions and methods for treating hepatitis C virus |
CA3131037A1 (fr) | 2011-11-30 | 2013-06-06 | Emory University | Inhibiteurs de jak antiviraux utiles dans le traitement ou la prevention d'infections retrovirales et autres infections virales |
SG11201402826YA (en) | 2011-12-22 | 2014-12-30 | Alios Biopharma Inc | Substituted nucleosides, nucleotides and analogs thereof |
AU2012358804B2 (en) | 2011-12-22 | 2018-04-19 | Alios Biopharma, Inc. | Substituted phosphorothioate nucleotide analogs |
WO2013133927A1 (fr) | 2012-02-13 | 2013-09-12 | Idenix Pharmaceuticals, Inc. | Compositions pharmaceutiques de 2'-c-méthyl-guanosine, 5'-[2-[(3-hydroxy-2,2-diméthyl-1-oxopropyl)thio]éthyl n-(phénylméthyl)phosphoramidate] |
WO2013123138A2 (fr) | 2012-02-14 | 2013-08-22 | University Of Georgia Research Foundation, Inc. | Spiro[2,4]heptanes destinés au traitement d'infections par flavivirus |
WO2013142124A1 (fr) | 2012-03-21 | 2013-09-26 | Vertex Pharmaceuticals Incorporated | Formes solides d'un promédicament nucléotidique thiophosphoramidate |
US9441007B2 (en) | 2012-03-21 | 2016-09-13 | Alios Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
USRE48171E1 (en) | 2012-03-21 | 2020-08-25 | Janssen Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
US9012427B2 (en) | 2012-03-22 | 2015-04-21 | Alios Biopharma, Inc. | Pharmaceutical combinations comprising a thionucleotide analog |
AU2013266393B2 (en) | 2012-05-22 | 2017-09-28 | Idenix Pharmaceuticals Llc | D-amino acid compounds for liver disease |
WO2013177195A1 (fr) | 2012-05-22 | 2013-11-28 | Idenix Pharmaceuticals, Inc. | Promédicaments de 3',5'-phosphate cyclique pour traiter une infection par le virus de l'hépatite c |
US9109001B2 (en) | 2012-05-22 | 2015-08-18 | Idenix Pharmaceuticals, Inc. | 3′,5′-cyclic phosphoramidate prodrugs for HCV infection |
EA027929B1 (ru) | 2012-05-25 | 2017-09-29 | Янссен Сайенсиз Айрлэнд Юси | Нуклеозиды на основе урацила и спирооксетана |
EP2900682A1 (fr) | 2012-09-27 | 2015-08-05 | IDENIX Pharmaceuticals, Inc. | Esters et malonates de promédicaments à base de s-acyl-2-thioéthyle (sate) |
US10513534B2 (en) | 2012-10-08 | 2019-12-24 | Idenix Pharmaceuticals Llc | 2′-chloro nucleoside analogs for HCV infection |
EP2909223B1 (fr) | 2012-10-19 | 2017-03-22 | Idenix Pharmaceuticals LLC | Composés dinucléotides contre une infection par le vhc |
US10723754B2 (en) | 2012-10-22 | 2020-07-28 | Idenix Pharmaceuticals Llc | 2′,4′-bridged nucleosides for HCV infection |
JP2015536954A (ja) * | 2012-11-07 | 2015-12-24 | ズカイ スオ | 置換ゲムシタビンアリールアミド類似体 |
US20140140951A1 (en) | 2012-11-14 | 2014-05-22 | Idenix Pharmaceuticals, Inc. | D-Alanine Ester of Rp-Nucleoside Analog |
EP2938624A1 (fr) | 2012-11-14 | 2015-11-04 | IDENIX Pharmaceuticals, Inc. | Ester de d-alanine d'analogue de sp-nucléoside |
EP2935304A1 (fr) | 2012-12-19 | 2015-10-28 | IDENIX Pharmaceuticals, Inc. | 4'-fluoro-nucléosides pour le traitement du vhc |
KR20140119012A (ko) | 2013-01-31 | 2014-10-08 | 길리어드 파마셋 엘엘씨 | 두 항바이러스 화합물의 병용 제형물 |
US10034893B2 (en) * | 2013-02-01 | 2018-07-31 | Enanta Pharmaceuticals, Inc. | 5, 6-D2 uridine nucleoside/tide derivatives |
WO2014121417A1 (fr) | 2013-02-07 | 2014-08-14 | Merck Sharp & Dohme Corp. | Composés hétérocycliques tétracycliques et leurs procédés d'utilisation pour le traitement de l'hépatite c |
WO2014121418A1 (fr) | 2013-02-07 | 2014-08-14 | Merck Sharp & Dohme Corp. | Composés hétérocycliques tétracycliques et leurs méthodes d'utilisation pour le traitement de l'hépatite c |
WO2014137930A1 (fr) | 2013-03-04 | 2014-09-12 | Idenix Pharmaceuticals, Inc. | Nucléosides de thiophosphate pour le traitement du vhc |
EP2970358B1 (fr) | 2013-03-04 | 2021-06-30 | Idenix Pharmaceuticals LLC | 3'-désoxynucléosides utilisables en vue du traitement d'une infection par le vhc |
EP2970357A1 (fr) | 2013-03-13 | 2016-01-20 | IDENIX Pharmaceuticals, Inc. | Pronucléotides de phosphoramidate d'acide aminé de 2'-cyano, azido et amino nucléosides pour le traitement du virus de l'hépatite c (vhc) |
WO2014165542A1 (fr) | 2013-04-01 | 2014-10-09 | Idenix Pharmaceuticals, Inc. | 2',4'-fluoronucléosides pour le traitement du vhc |
CN105377868A (zh) | 2013-04-12 | 2016-03-02 | 艾其林医药公司 | 用于治疗hcv的高活性核苷衍生物 |
WO2014197578A1 (fr) | 2013-06-05 | 2014-12-11 | Idenix Pharmaceuticals, Inc. | 1',4'-thio nucléosides pour le traitement du virus de l'hépatite c (vhc) |
WO2015017713A1 (fr) | 2013-08-01 | 2015-02-05 | Idenix Pharmaceuticals, Inc. | Pronucléotides phosphoramidates avec acides aminés d de composés halogéno pyrimidines pour le traitement des hépatopathies |
ES2900570T3 (es) | 2013-08-27 | 2022-03-17 | Gilead Pharmasset Llc | Formulación de combinación de dos compuestos antivirales |
EP3046924A1 (fr) | 2013-09-20 | 2016-07-27 | IDENIX Pharmaceuticals, Inc. | Inhibiteurs du virus de l'hépatite c |
WO2015061683A1 (fr) | 2013-10-25 | 2015-04-30 | Idenix Pharmaceuticals, Inc. | Pronucléotides thiophosphoramidates à acide aminé d et pronucléotides thiophosphoramidates à d-analine de composés de nucléoside utiles pour le traitement du vhc |
WO2015066370A1 (fr) | 2013-11-01 | 2015-05-07 | Idenix Pharmaceuticals, Inc. | Pronucléotides phosphoramidates de d-alanine de composés de nucléoside 2'-méthyl 2'-fluoro guanosine dans le traitement du vhc |
WO2015081297A1 (fr) | 2013-11-27 | 2015-06-04 | Idenix Pharmaceuticals, Inc. | Analogues de nucléoside 2'-dichloro et 2'-fluoro-2'-chloro analogues pour l'infection par le vhc |
EP3083654A1 (fr) | 2013-12-18 | 2016-10-26 | Idenix Pharmaceuticals LLC | Nucléosides 4'-or pour le traitement du vhc |
EP3105238A4 (fr) | 2014-02-13 | 2017-11-08 | Ligand Pharmaceuticals, Inc. | Composés de promédicaments et leurs utilisations |
WO2015134560A1 (fr) | 2014-03-05 | 2015-09-11 | Idenix Pharmaceuticals, Inc. | Formes solides d'un composé inhibiteur des virus de la famille des flaviviridae et sels de celui-ci |
EP3113763A1 (fr) | 2014-03-05 | 2017-01-11 | Idenix Pharmaceuticals LLC | Formes solides de promédicaments de 2'-chloro-2'-méthyl uridine pour lutter contre le vhc |
WO2015134561A1 (fr) | 2014-03-05 | 2015-09-11 | Idenix Pharmaceuticals, Inc. | Compositions pharmaceutiques comprenant un inhibiteur de flaviviridae hétéroarylène fusionné en 5,5 et son utilisation pour le traitement ou la prévention d'une infection par les flaviviridae |
EP3131914B1 (fr) | 2014-04-16 | 2023-05-10 | Idenix Pharmaceuticals LLC | Nucléosides méthyle ou alcynyle substitués en position 3 pour le traitement du virus de l'hépatite c |
WO2015191303A2 (fr) * | 2014-06-10 | 2015-12-17 | Agilent Technologies, Inc. | Groupes protecteurs pour le « nucléotide z » et procédés associés |
WO2016003812A1 (fr) | 2014-07-02 | 2016-01-07 | Ligand Pharmaceuticals, Inc. | Composés de promédicaments et leurs utilisations |
WO2016033164A1 (fr) | 2014-08-26 | 2016-03-03 | Enanta Pharmaceuticals, Inc. | Dérivés de nucléosides et de nucléotides |
WO2016073756A1 (fr) | 2014-11-06 | 2016-05-12 | Enanta Pharmaceuticals, Inc. | Dérivés de nucléosides/nucléotides deutérés |
US9732110B2 (en) | 2014-12-05 | 2017-08-15 | Enanta Pharmaceuticals, Inc. | Nucleoside and nucleotide derivatives |
GEP20247600B (en) | 2015-03-06 | 2024-02-26 | Atea Pharmaceuticals Inc | B-D-2'-DEOXY-2'a-FLUORO-2'-B-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT |
CN106146588A (zh) * | 2015-03-26 | 2016-11-23 | 常州制药厂有限公司 | 一种索非布韦的制备方法 |
EP3344642A1 (fr) * | 2015-09-02 | 2018-07-11 | AbbVie Inc. | Dérivés anti-viraux de tétrahydrofurane |
EP3455218A4 (fr) | 2016-05-10 | 2019-12-18 | C4 Therapeutics, Inc. | Dégronimères de type glutarimide liés au carbone c3 pour la dégradation de protéines cibles |
WO2017197036A1 (fr) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Dégronimères spirocycliques pour la dégradation de protéines cibles |
EP3454856B1 (fr) | 2016-05-10 | 2024-09-11 | C4 Therapeutics, Inc. | Dégronimères hétérocycliques pour la dégradation de protéines cibles |
US10711029B2 (en) | 2016-07-14 | 2020-07-14 | Atea Pharmaceuticals, Inc. | Beta-d-2′-deoxy-2′-alpha-fluoro-2′-beta-c-substituted-4′fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection |
EP3512863B1 (fr) | 2016-09-07 | 2021-12-08 | ATEA Pharmaceuticals, Inc. | 2'-substitué-n6-substitués nucléotides de purine pour le traitement de virus à arn |
CN106432388B (zh) * | 2016-09-14 | 2018-11-30 | 江苏福瑞生物医药有限公司 | (2’r) -2’-脱氧-2’-氟- 2’-甲基脲苷的制备方法 |
SG11201906163TA (en) | 2017-02-01 | 2019-08-27 | Atea Pharmaceuticals Inc | Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus |
US10435429B2 (en) | 2017-10-03 | 2019-10-08 | Nucorion Pharmaceuticals, Inc. | 5-fluorouridine monophosphate cyclic triester compounds |
CN111788196A (zh) | 2018-01-09 | 2020-10-16 | 配体药物公司 | 缩醛化合物及其治疗用途 |
CA3088287A1 (fr) | 2018-01-10 | 2019-07-18 | Nucorion Pharmaceuticals, Inc. | Composes de phosphore(n)amidatacetal et phosph(on)atalcetal |
US11427550B2 (en) | 2018-01-19 | 2022-08-30 | Nucorion Pharmaceuticals, Inc. | 5-fluorouracil compounds |
EP3773753A4 (fr) | 2018-04-10 | 2021-12-22 | ATEA Pharmaceuticals, Inc. | Traitement de patients infectés par le virus de l'hépatite c avec une cirrhose |
US12110311B2 (en) | 2019-07-17 | 2024-10-08 | Nucorion Pharmaceuticals, Inc. | Cyclic deoxyribonucleotide compounds |
US10874687B1 (en) | 2020-02-27 | 2020-12-29 | Atea Pharmaceuticals, Inc. | Highly active compounds against COVID-19 |
WO2021216427A1 (fr) | 2020-04-21 | 2021-10-28 | Ligand Pharmaceuticals, Inc. | Composés de promédicaments nucléotidiques |
Family Cites Families (180)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6458772B1 (en) | 1909-10-07 | 2002-10-01 | Medivir Ab | Prodrugs |
US3074929A (en) * | 1955-08-11 | 1963-01-22 | Burroughs Wellcome Co | Glycosides of 6-mercaptopurine |
GB924246A (en) | 1958-12-23 | 1963-04-24 | Wellcome Found | Purine derivatives and their preparation |
US3116282A (en) | 1960-04-27 | 1963-12-31 | Upjohn Co | Pyrimidine nucleosides and process |
GB984877A (en) | 1962-08-16 | 1965-03-03 | Waldhof Zellstoff Fab | Improvements in and relating to 6-halonucleosides |
FR1498856A (fr) | 1965-11-15 | 1968-01-10 | ||
GB1163103A (en) | 1965-11-15 | 1969-09-04 | Merck & Co Inc | Ribofuranosyl Purine Derivatives |
FR1521076A (fr) | 1966-05-02 | 1968-04-12 | Merck & Co Inc | Nucléosides de purines substituées |
DE1695411A1 (de) | 1966-05-02 | 1971-04-15 | Merck & Co Inc | Substituierte Purin-Nucleoside und Verfahren zu deren Herstellung |
US3480613A (en) | 1967-07-03 | 1969-11-25 | Merck & Co Inc | 2-c or 3-c-alkylribofuranosyl - 1-substituted compounds and the nucleosides thereof |
DE2122991C2 (de) | 1971-05-04 | 1982-06-09 | Schering Ag, 1000 Berlin Und 4619 Bergkamen | Verfahren zur Herstellung von Cytosin- und 6-Azacytosinnucleosiden |
US3798209A (en) | 1971-06-01 | 1974-03-19 | Icn Pharmaceuticals | 1,2,4-triazole nucleosides |
USRE29835E (en) | 1971-06-01 | 1978-11-14 | Icn Pharmaceuticals | 1,2,4-Triazole nucleosides |
US4022889A (en) * | 1974-05-20 | 1977-05-10 | The Upjohn Company | Therapeutic compositions of antibiotic U-44,590 and methods for using the same |
DE2508312A1 (de) | 1975-02-24 | 1976-09-02 | Schering Ag | Neues verfahren zur herstellung von nucleosiden |
US4058602A (en) | 1976-08-09 | 1977-11-15 | The United States Of America As Represented By The Department Of Health, Education And Welfare | Synthesis, structure, and antitumor activity of 5,6-dihydro-5-azacytidine |
DE2757365A1 (de) * | 1977-12-20 | 1979-06-21 | Schering Ag | Neues verfahren zur herstellung von nucleosiden |
DE2852721A1 (de) | 1978-12-06 | 1980-06-26 | Basf Ag | Verfahren zur reindarstellung von kaliumribonat und ribonolacton |
US4239753A (en) | 1978-12-12 | 1980-12-16 | The Upjohn Company | Composition of matter and process |
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
US4540707A (en) * | 1983-01-28 | 1985-09-10 | Bayer Aktiengesellschaft | Nafazatrom as a lipoxygenase inhibitor |
FR2562543B1 (fr) | 1984-04-10 | 1987-09-25 | Elf Aquitaine | Nouveaux phosphonites cycliques, leur preparation et applications |
NL8403224A (nl) | 1984-10-24 | 1986-05-16 | Oce Andeno Bv | Dioxafosforinanen, de bereiding ervan en de toepassing voor het splitsen van optisch actieve verbindingen. |
JPS61204193A (ja) | 1985-03-05 | 1986-09-10 | Takeda Chem Ind Ltd | シトシンヌクレオシド類の製造法 |
US6448392B1 (en) | 1985-03-06 | 2002-09-10 | Chimerix, Inc. | Lipid derivatives of antiviral nucleosides: liposomal incorporation and method of use |
US5223263A (en) | 1988-07-07 | 1993-06-29 | Vical, Inc. | Liponucleotide-containing liposomes |
US4605659A (en) | 1985-04-30 | 1986-08-12 | Syntex (U.S.A.) Inc. | Purinyl or pyrimidinyl substituted hydroxycyclopentane compounds useful as antivirals |
US4754026A (en) * | 1985-06-04 | 1988-06-28 | Takeda Chemical Industries, Ltd. | Conversion of uracil derivatives to cytosine derivatives |
DE3714473A1 (de) | 1987-04-30 | 1988-11-10 | Basf Ag | Kontinuierliches verfahren zur epimerisierung von zuckern, insbesondere von d-arabinose zu d-ribose |
GB8719367D0 (en) | 1987-08-15 | 1987-09-23 | Wellcome Found | Therapeutic compounds |
US5246924A (en) | 1987-09-03 | 1993-09-21 | Sloan-Kettering Institute For Cancer Research | Method for treating hepatitis B virus infections using 1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)-5-ethyluracil |
WO1989002733A1 (fr) | 1987-09-22 | 1989-04-06 | The Regents Of The University Of California | Analogues de nucleosides liposomiques pour le traitement du sida |
US4880784A (en) | 1987-12-21 | 1989-11-14 | Brigham Young University | Antiviral methods utilizing ribofuranosylthiazolo[4,5-d]pyrimdine derivatives |
US4852740A (en) * | 1988-03-11 | 1989-08-01 | Information Packaging Corp. | Holder for flat objects such as computer disks |
US5122517A (en) | 1988-06-10 | 1992-06-16 | Regents Of The University Of Minnesota | Antiviral combination comprising nucleoside analogs |
GB8815265D0 (en) * | 1988-06-27 | 1988-08-03 | Wellcome Found | Therapeutic nucleosides |
US6599887B2 (en) | 1988-07-07 | 2003-07-29 | Chimerix, Inc. | Methods of treating viral infections using antiviral liponucleotides |
US6252060B1 (en) | 1988-07-07 | 2001-06-26 | Nexstar Pharmaceuticals, Inc. | Antiviral liponucleosides: treatment of hepatitis B |
SE8802687D0 (sv) | 1988-07-20 | 1988-07-20 | Astra Ab | Nucleoside derivatives |
US5744600A (en) * | 1988-11-14 | 1998-04-28 | Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic | Phosphonomethoxy carbocyclic nucleosides and nucleotides |
US5616702A (en) | 1988-11-15 | 1997-04-01 | Merrell Pharmaceuticals Inc. | 2-'-ethenylidene cytidine, uridine and guanosine derivatives |
US5705363A (en) * | 1989-03-02 | 1998-01-06 | The Women's Research Institute | Recombinant production of human interferon τ polypeptides and nucleic acids |
US5194654A (en) | 1989-11-22 | 1993-03-16 | Vical, Inc. | Lipid derivatives of phosphonoacids for liposomal incorporation and method of use |
US5411947A (en) | 1989-06-28 | 1995-05-02 | Vestar, Inc. | Method of converting a drug to an orally available form by covalently bonding a lipid to the drug |
US5463092A (en) | 1989-11-22 | 1995-10-31 | Vestar, Inc. | Lipid derivatives of phosphonacids for liposomal incorporation and method of use |
US6060592A (en) | 1990-01-11 | 2000-05-09 | Isis Pharmaceuticals, Inc. | Pyrimidine nucleoside compounds and oligonucleoside compounds containing same |
US5200514A (en) * | 1990-01-19 | 1993-04-06 | University Of Georgia Research Foundation, Inc. | Synthesis of 2'-deoxypyrimidine nucleosides |
US5204466A (en) * | 1990-02-01 | 1993-04-20 | Emory University | Method and compositions for the synthesis of bch-189 and related compounds |
AU7872491A (en) | 1990-05-07 | 1991-11-27 | Vical, Inc. | Lipid prodrugs of salicylate and nonsteroidal anti-inflammatory drugs |
FR2662165B1 (fr) | 1990-05-18 | 1992-09-11 | Univ Paris Curie | Derives nucleosidiques branches, leur procede de preparation et leur utilisation a titre de medicament. |
CA2083961A1 (fr) * | 1990-05-29 | 1991-11-30 | Henk Van Den Bosch | Synthese de derives de di- et de triphosphate de glycerol |
EP0531452A4 (en) | 1990-05-29 | 1993-06-09 | Vical, Inc. | Synthesis of glycerol di- and triphosphate derivatives |
DK0533833T3 (da) | 1990-06-13 | 1996-04-22 | Arnold Glazier | Phosphorprolægemidler |
US5627165A (en) | 1990-06-13 | 1997-05-06 | Drug Innovation & Design, Inc. | Phosphorous prodrugs and therapeutic delivery systems using same |
US5372808A (en) | 1990-10-17 | 1994-12-13 | Amgen Inc. | Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect |
US5256641A (en) | 1990-11-01 | 1993-10-26 | State Of Oregon | Covalent polar lipid-peptide conjugates for immunological targeting |
US5543390A (en) | 1990-11-01 | 1996-08-06 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University | Covalent microparticle-drug conjugates for biological targeting |
US5543389A (en) | 1990-11-01 | 1996-08-06 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University, A Non Profit Organization | Covalent polar lipid-peptide conjugates for use in salves |
US5149794A (en) | 1990-11-01 | 1992-09-22 | State Of Oregon | Covalent lipid-drug conjugates for drug targeting |
US5827819A (en) | 1990-11-01 | 1998-10-27 | Oregon Health Sciences University | Covalent polar lipid conjugates with neurologically active compounds for targeting |
IL100502A (en) | 1991-01-03 | 1995-12-08 | Iaf Biochem Int | PHARMACEUTICAL PREPARATIONS CONTAINING CIS-4-AMINO-1-) 2-HYDROXIMETHIL-1,3-OXETYOLEN-5-IL (- |
JPH04266880A (ja) | 1991-02-22 | 1992-09-22 | Japan Tobacco Inc | 3 −dpa− ラクトンの製造方法 |
US5157027A (en) | 1991-05-13 | 1992-10-20 | E. R. Squibb & Sons, Inc. | Bisphosphonate squalene synthetase inhibitors and method |
JPH07500573A (ja) | 1991-07-12 | 1995-01-19 | ネクススター・ファーマシューティカルズ・インコーポレイテッド | 抗ウィルス性リポヌクレオシド:b型肝炎の治療 |
JPH0525152A (ja) | 1991-07-22 | 1993-02-02 | Japan Tobacco Inc | 3−dpa−ラクトンの製造法 |
US5554728A (en) | 1991-07-23 | 1996-09-10 | Nexstar Pharmaceuticals, Inc. | Lipid conjugates of therapeutic peptides and protease inhibitors |
TW224053B (fr) | 1991-09-13 | 1994-05-21 | Paul B Chretien | |
US5676942A (en) | 1992-02-10 | 1997-10-14 | Interferon Sciences, Inc. | Composition containing human alpha interferon species proteins and method for use thereof |
US5606048A (en) | 1992-06-22 | 1997-02-25 | Eli Lilly And Company | Stereoselective glycosylation process for preparing 2'-Deoxy-2', 2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides |
US5821357A (en) | 1992-06-22 | 1998-10-13 | Eli Lilly And Company | Stereoselective glycosylation process for preparing 2'-deoxy-2',2'-difluoropurine and triazole nucleosides |
US5256797A (en) | 1992-06-22 | 1993-10-26 | Eli Lilly And Company | Process for separating 2-deoxy-2,2-difluoro-D-ribofuranosyl alkylsulfonate anomers |
US5371210A (en) | 1992-06-22 | 1994-12-06 | Eli Lilly And Company | Stereoselective fusion glycosylation process for preparing 2'-deoxy-2',2'-difluoronucleosides and 2'-deoxy-2'-fluoronucleosides |
US5401861A (en) | 1992-06-22 | 1995-03-28 | Eli Lilly And Company | Low temperature process for preparing alpha-anomer enriched 2-deoxy-2,2-difluoro-D-ribofuranosyl sulfonates |
DE4224737A1 (de) | 1992-07-27 | 1994-02-03 | Herbert Prof Dr Schott | Neue Cytosinnucleosidanaloga, Verfahren zu ihrer Herstellung und ihre Verwendung |
KR100252451B1 (ko) | 1992-09-01 | 2000-04-15 | 피터 지. 스트링거 | 뉴클레오사이드의아노머화방법 |
GB9226729D0 (en) | 1992-12-22 | 1993-02-17 | Wellcome Found | Therapeutic combination |
GB9307043D0 (en) | 1993-04-05 | 1993-05-26 | Norsk Hydro As | Chemical compounds |
WO1994026273A1 (fr) | 1993-05-12 | 1994-11-24 | Hostetler Karl Y | Derives d'acyclovir a usage topique |
US6156501A (en) | 1993-10-26 | 2000-12-05 | Affymetrix, Inc. | Arrays of modified nucleic acid probes and methods of use |
US5587362A (en) | 1994-01-28 | 1996-12-24 | Univ. Of Ga Research Foundation | L-nucleosides |
US5696277A (en) | 1994-11-15 | 1997-12-09 | Karl Y. Hostetler | Antiviral prodrugs |
WO1996018636A1 (fr) | 1994-12-13 | 1996-06-20 | Taiho Pharmaceutical Co., Ltd. | Derives de nucleoside substitues en 3' |
DE19513330A1 (de) * | 1995-04-03 | 1996-10-10 | Schering Ag | Neues Verfahren zur Herstellung von Nucleosiden |
US5977061A (en) | 1995-04-21 | 1999-11-02 | Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic | N6 - substituted nucleotide analagues and their use |
DE69638137D1 (de) | 1995-09-07 | 2010-04-15 | Univ Georgia | Therapeutische azidverbindungen |
US5908621A (en) | 1995-11-02 | 1999-06-01 | Schering Corporation | Polyethylene glycol modified interferon therapy |
US5980884A (en) | 1996-02-05 | 1999-11-09 | Amgen, Inc. | Methods for retreatment of patients afflicted with Hepatitis C using consensus interferon |
GB9609932D0 (en) | 1996-05-13 | 1996-07-17 | Hoffmann La Roche | Use of IL-12 and IFN alpha for the treatment of infectious diseases |
SK284054B6 (sk) * | 1996-10-16 | 2004-08-03 | Icn Pharmaceuticals, Inc. | Substituované triazolové nukleozidy, farmaceutický prostriedok s ich obsahom a ich použitie |
JP2001525797A (ja) | 1996-10-28 | 2001-12-11 | ザ ユニバーシティ オブ ワシントン | ウイルスrnaへのミスコーディングリボヌクレオシドアナログの組込みによるウイルス変異の誘導 |
US6248878B1 (en) * | 1996-12-24 | 2001-06-19 | Ribozyme Pharmaceuticals, Inc. | Nucleoside analogs |
US6172046B1 (en) * | 1997-09-21 | 2001-01-09 | Schering Corporation | Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection |
US6472373B1 (en) | 1997-09-21 | 2002-10-29 | Schering Corporation | Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection |
EP1136075B1 (fr) | 1997-09-21 | 2003-01-15 | Schering Corporation | Thérapie combinée pour l' éradication de l' HCV-ARN détectable chez des patients atteints d' une infection d' hépatite C chronique |
KR100263166B1 (ko) * | 1997-09-30 | 2000-08-01 | 윤종용 | 촬영신호 전송방법 및 전송장치 |
ES2276515T3 (es) * | 1998-02-25 | 2007-06-16 | Emory University | 2'-fluoronucleosidos. |
WO1999045016A2 (fr) | 1998-03-06 | 1999-09-10 | Metabasis Therapeutics, Inc. | Nouveaux promedicaments pour composes contenant du phosphore |
US6312662B1 (en) | 1998-03-06 | 2001-11-06 | Metabasis Therapeutics, Inc. | Prodrugs phosphorus-containing compounds |
KR100389853B1 (ko) | 1998-03-06 | 2003-08-19 | 삼성전자주식회사 | 카타로그정보의기록및재생방법 |
BR9910505A (pt) | 1998-05-15 | 2001-01-02 | Schering Corp | Terapia de combinação compreendendo ribavirina e interferon alfa em pacientes cândidos de tratamento antiviral tendo infecção crÈnica por hepatite c |
US6833361B2 (en) * | 1998-05-26 | 2004-12-21 | Ribapharm, Inc. | Nucleosides having bicyclic sugar moiety |
ATE307597T1 (de) * | 1998-06-08 | 2005-11-15 | Hoffmann La Roche | Verwendung von peg-ifn-alpha und ribavirin zur behandlung chronischer hepatitis c |
US6444652B1 (en) | 1998-08-10 | 2002-09-03 | Novirio Pharmaceuticals Limited | β-L-2'-deoxy-nucleosides for the treatment of hepatitis B |
MXPA01001507A (es) | 1998-08-10 | 2003-09-10 | Novirio Pharmaceuticals Ltd | °l-2'desoxi-nucleosidos para el tratamiento de hepatitis b. |
JP2002525295A (ja) * | 1998-09-25 | 2002-08-13 | バイロファーマ・インコーポレイテッド | ウイルス感染および関連疾患の治療または予防法 |
CA2252144A1 (fr) | 1998-10-16 | 2000-04-16 | University Of Alberta | Prodrogues anticancer a action double |
US6277830B1 (en) | 1998-10-16 | 2001-08-21 | Schering Corporation | 5′-amino acid esters of ribavirin and the use of same to treat hepatitis C with interferon |
FR2784892B1 (fr) | 1998-10-23 | 2001-04-06 | Smith & Nephew Kinetec Sa | Attelle de mobilisation passive repliable pour membre inferieur |
KR100618028B1 (ko) | 1998-11-05 | 2006-08-30 | 쌍트르 나쉬오날 드 라 르쉐르스 쉬앙티피끄 | 항-b형 간염 활성을 가진 뉴클레오시드 |
AR021876A1 (es) | 1998-12-18 | 2002-08-07 | Schering Corp | Terapia de combinacion para vhc por induccion de ribavirina - interferon alfa pegilado |
JP2002537396A (ja) * | 1999-02-22 | 2002-11-05 | バイオケム ファーマ インコーポレイテッド | 抗ウィルス活性を有する[1,8]ナフチリジン誘導体 |
CN1321999C (zh) | 1999-03-05 | 2007-06-20 | 症变治疗公司 | 新的含磷前药 |
US6831069B2 (en) | 1999-08-27 | 2004-12-14 | Ribapharm Inc. | Pyrrolo[2,3-d]pyrimidine nucleoside analogs |
WO2001018013A1 (fr) | 1999-09-08 | 2001-03-15 | Metabasis Therapeutics, Inc. | Promedicaments destines a l'administration specifique de medicaments au foie |
CA2389745C (fr) | 1999-11-04 | 2010-03-23 | Shire Biochem Inc. | Procede de traitement ou de prevention de l'infection virale par flaviviridae faisant appel a des analogues des nucleosides |
JP2003519154A (ja) | 1999-12-22 | 2003-06-17 | メタバシス・セラピューティクス・インコーポレイテッド | 新規なビスアミダートホスホネートプロドラッグ |
US7056895B2 (en) * | 2000-02-15 | 2006-06-06 | Valeant Pharmaceuticals International | Tirazole nucleoside analogs and methods for using same |
US6495677B1 (en) | 2000-02-15 | 2002-12-17 | Kanda S. Ramasamy | Nucleoside compounds |
US6455508B1 (en) | 2000-02-15 | 2002-09-24 | Kanda S. Ramasamy | Methods for treating diseases with tirazole and pyrrolo-pyrimidine ribofuranosyl nucleosides |
CN1427722A (zh) | 2000-02-18 | 2003-07-02 | 希拉生物化学股份有限公司 | 用核苷类似物治疗或预防黄病毒感染的方法 |
BR0110023A (pt) * | 2000-04-13 | 2003-12-30 | Pharmasset Ltd | Derivados de nucleosìdeo 3'-ou-2' substituìdos para tratamento de infecções por vìrus da hepatite |
AU2001255495A1 (en) * | 2000-04-20 | 2001-11-07 | Schering Corporation | Ribavirin-interferon alfa combination therapy for eradicating detectable hcv-rnain patients having chronic hepatitis c infection |
MY164523A (en) * | 2000-05-23 | 2017-12-29 | Univ Degli Studi Cagliari | Methods and compositions for treating hepatitis c virus |
JP5230052B2 (ja) * | 2000-05-26 | 2013-07-10 | イデニクス(ケイマン)リミテツド | フラビウイルスおよびペスチウイルス治療のための方法および組成物 |
ATE275406T1 (de) | 2000-05-26 | 2004-09-15 | Idenix Cayman Ltd | Methoden zur behandlung von delta hepatitis virus infektionen mit beta-l-2' deoxy-nucleosiden |
US6787526B1 (en) | 2000-05-26 | 2004-09-07 | Idenix Pharmaceuticals, Inc. | Methods of treating hepatitis delta virus infection with β-L-2′-deoxy-nucleosides |
MY141594A (en) * | 2000-06-15 | 2010-05-14 | Novirio Pharmaceuticals Ltd | 3'-PRODRUGS OF 2'-DEOXY-ß-L-NUCLEOSIDES |
US6875751B2 (en) * | 2000-06-15 | 2005-04-05 | Idenix Pharmaceuticals, Inc. | 3′-prodrugs of 2′-deoxy-β-L-nucleosides |
US6815542B2 (en) | 2000-06-16 | 2004-11-09 | Ribapharm, Inc. | Nucleoside compounds and uses thereof |
US6403584B1 (en) * | 2000-06-22 | 2002-06-11 | Merck & Co., Inc. | Substituted nipecotyl derivatives as inhibitors of cell adhesion |
US20030008841A1 (en) * | 2000-08-30 | 2003-01-09 | Rene Devos | Anti-HCV nucleoside derivatives |
CA2318667C (fr) * | 2000-09-11 | 2004-02-24 | Fci Canada Inc. | Photocoupleur a semiconducteurs monolithiques incorporant une rainure d'alignement de fibre optique |
EP1411954B1 (fr) * | 2000-10-18 | 2010-12-15 | Pharmasset, Inc. | Nucleosides modifies pour traiter des infections virales et une proliferation cellulaire anormale |
EP2141244A1 (fr) * | 2000-10-18 | 2010-01-06 | Pharmasset, Inc. | Quantification simultanée d'acides nucléiques dans des cellules malades |
EP1326594A2 (fr) | 2000-10-18 | 2003-07-16 | Schering Corporation | Polytherapie a base de ribavirine et d'interferon alpha pegyle contre le virus de l'hepatite c |
US20040266723A1 (en) | 2000-12-15 | 2004-12-30 | Otto Michael J. | Antiviral agents for treatment of Flaviviridae infections |
EP1539188B1 (fr) * | 2001-01-22 | 2015-01-07 | Merck Sharp & Dohme Corp. | Derives de nucleoside comme inhibiteurs de l'arn polymerase virale arn-dependante |
US7105499B2 (en) * | 2001-01-22 | 2006-09-12 | Merck & Co., Inc. | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase |
US6669805B2 (en) * | 2001-02-16 | 2003-12-30 | International Business Machines Corporation | Drill stack formation |
CN1505635A (zh) | 2001-03-01 | 2004-06-16 | 2′,3′-二脱氧-2',3'-二脱氢核苷的合成方法 | |
GB0112617D0 (en) * | 2001-05-23 | 2001-07-18 | Hoffmann La Roche | Antiviral nucleoside derivatives |
GB0114286D0 (en) | 2001-06-12 | 2001-08-01 | Hoffmann La Roche | Nucleoside Derivatives |
AU2002322325A1 (en) | 2001-06-22 | 2003-01-08 | Emory University | Beta-2'-or 3'-halonucleosides |
WO2003024461A1 (fr) | 2001-09-20 | 2003-03-27 | Schering Corporation | Polytherapie de l'hepatite c |
JP2005536440A (ja) * | 2001-09-28 | 2005-12-02 | イデニクス(ケイマン)リミテツド | 4’位が修飾されたヌクレオシドを使用するフラビウイルスおよびペスチウイルスの治療のための方法および組成物 |
BR0214944A (pt) * | 2001-12-14 | 2005-06-07 | Pharmasset Ltd | Nucleosìdeos de n4-acilcitosina para o tratamento de infecções virais |
US6965066B1 (en) | 2002-01-16 | 2005-11-15 | Actodyne General, Inc. | Elongated string support for a stringed musical instrument |
US20040010717A1 (en) * | 2002-01-29 | 2004-01-15 | Intertainer Asia Pte Ltd. | Apparatus and method for preventing digital media piracy |
KR20040094692A (ko) * | 2002-02-14 | 2004-11-10 | 파마셋, 리미티드 | 변형된 불소화 뉴클레오사이드 유사체 |
JP2005525358A (ja) * | 2002-02-28 | 2005-08-25 | ビオタ インコーポレーティッド | ヌクレオチド模倣体およびそのプロドラッグ |
US7247621B2 (en) * | 2002-04-30 | 2007-07-24 | Valeant Research & Development | Antiviral phosphonate compounds and methods therefor |
KR20050006221A (ko) * | 2002-05-06 | 2005-01-15 | 제네랩스 테크놀로지스, 인코포레이티드 | C형 간염 바이러스 감염 치료용의 뉴클레오시드 유도체 |
EP1572945A2 (fr) | 2002-06-27 | 2005-09-14 | Merck & Co., Inc. | Derives nucleosidiques utilises comme inhibiteurs de l'arn polymerase arn-dependante virale |
JP5087211B2 (ja) * | 2002-06-28 | 2012-12-05 | イデニクス(ケイマン)リミテツド | フラビウィルス感染治療のための2′および3′−ヌクレオシドプロドラッグ |
WO2004002422A2 (fr) * | 2002-06-28 | 2004-01-08 | Idenix (Cayman) Limited | Ester 3'-l-valine de ?-d-2'-c-methyl-ribofuranosyl cytidine pour le traitement d'infections par des flaviviridae |
AU2003269902A1 (en) | 2002-07-16 | 2004-02-02 | Isis Pharmaceuticals, Inc. | Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase |
US7323449B2 (en) | 2002-07-24 | 2008-01-29 | Merck & Co., Inc. | Thionucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase |
US7094768B2 (en) * | 2002-09-30 | 2006-08-22 | Genelabs Technologies, Inc. | Nucleoside derivatives for treating hepatitis C virus infection |
WO2004028481A2 (fr) | 2002-09-30 | 2004-04-08 | Genelabs Technologies, Inc. | Derives nucleosidiques servant au traitement d'une infection par le virus de l'hepatite c |
CA2506129C (fr) * | 2002-11-15 | 2015-02-17 | Idenix (Cayman) Limited | Nucleoside a ramification en 2' et mutation de flaviviridae |
TWI332507B (en) * | 2002-11-19 | 2010-11-01 | Hoffmann La Roche | Antiviral nucleoside derivatives |
AU2003300901A1 (en) * | 2002-12-12 | 2004-06-30 | Idenix (Cayman) Limited | Process for the production of 2'-branched nucleosides |
KR20060008297A (ko) | 2003-03-20 | 2006-01-26 | 마이크로 바이올로지카 퀴미카 이 파마슈티카 리미티드 | 2'-데옥시-β-L-뉴클레오시드의 제조방법 |
US20040259934A1 (en) | 2003-05-01 | 2004-12-23 | Olsen David B. | Inhibiting Coronaviridae viral replication and treating Coronaviridae viral infection with nucleoside compounds |
US20040229839A1 (en) | 2003-05-14 | 2004-11-18 | Biocryst Pharmaceuticals, Inc. | Substituted nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases |
WO2005003147A2 (fr) * | 2003-05-30 | 2005-01-13 | Pharmasset, Inc. | Analogues de nucleosides fluores modifies |
KR20060026426A (ko) * | 2003-06-19 | 2006-03-23 | 에프. 호프만-라 로슈 아게 | 4'-아지도 뉴클레오사이드 유도체의 제조 방법 |
US7151089B2 (en) * | 2003-10-27 | 2006-12-19 | Genelabs Technologies, Inc. | Nucleoside compounds for treating viral infections |
US20050137141A1 (en) * | 2003-10-24 | 2005-06-23 | John Hilfinger | Prodrug composition |
KR20060096487A (ko) * | 2003-10-27 | 2006-09-11 | 진랩스 테크놀러지스, 인크. | 바이러스 감염증들을 치료하기 위한 뉴클레오시드 화합물 |
CA2543090A1 (fr) | 2003-10-27 | 2005-06-16 | Genelabs Technologies, Inc. | Composes nucleosidiques de traitement d'infections virales |
CN101023094B (zh) | 2004-07-21 | 2011-05-18 | 法莫赛特股份有限公司 | 烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备 |
EP2348029A1 (fr) | 2004-07-21 | 2011-07-27 | Pharmasset, Inc. | Preparation de pyrimidines et purines 2-desoxy-2-fluoro-d-ribofuranosyl substitues en alkyle et leurs dérives |
DE602005015466D1 (de) * | 2004-08-23 | 2009-08-27 | Hoffmann La Roche | Antivirale 4'-azidonucleoside |
US7544632B2 (en) * | 2004-09-22 | 2009-06-09 | Exxonmobil Research And Engineering Company | Bulk Ni-Mo-W catalysts made from precursors containing an organic agent |
WO2006121468A1 (fr) * | 2004-11-22 | 2006-11-16 | Genelabs Technologies, Inc. | Composes 5-nitro-nucleoside pour le traitement des infections virales |
US20060194835A1 (en) | 2005-02-09 | 2006-08-31 | Migenix Inc. | Compositions and methods for treating or preventing flaviviridae infections |
DE102005012681A1 (de) | 2005-03-18 | 2006-09-21 | Weber, Lutz, Dr. | Neue 1,5-Dihydro-pyrrol-2-one |
WO2006116557A1 (fr) | 2005-04-25 | 2006-11-02 | Genelabs Technologies, Inc. | Composes nucleosides pour le traitement d’infections virales |
WO2007075876A2 (fr) | 2005-12-23 | 2007-07-05 | Idenix Pharmaceuticals, Inc. | Procede pour la preparation d’un intermediaire synthetique pour la preparation de nucleosides ramifies |
-
2003
- 2003-06-27 WO PCT/US2003/020431 patent/WO2004002422A2/fr active Search and Examination
- 2003-06-27 EP EP03762183A patent/EP1536804A4/fr not_active Withdrawn
- 2003-06-27 AU AU2003248748A patent/AU2003248748A1/en not_active Abandoned
- 2003-06-27 BR BRPI0312278-6A patent/BR0312278A/pt not_active IP Right Cessation
- 2003-06-27 CA CA002489552A patent/CA2489552A1/fr not_active Abandoned
- 2003-06-27 PL PL03374781A patent/PL374781A1/xx not_active Application Discontinuation
- 2003-06-27 KR KR1020047021073A patent/KR20050035194A/ko not_active Application Discontinuation
- 2003-06-27 RS YUP-1139/04A patent/RS113904A/sr unknown
- 2003-06-27 CN CNA03820701XA patent/CN1678326A/zh active Pending
- 2003-06-27 JP JP2004518041A patent/JP2005533824A/ja active Pending
- 2003-06-27 US US10/607,909 patent/US7456155B2/en not_active Expired - Lifetime
- 2003-06-27 MX MXPA04012802A patent/MXPA04012802A/es not_active Application Discontinuation
- 2003-06-27 US US10/609,298 patent/US7662798B2/en not_active Expired - Fee Related
- 2003-06-27 AP AP2005003213A patent/AP2005003213A0/xx unknown
-
2004
- 2004-12-06 US US11/005,472 patent/US20070060505A1/en not_active Abandoned
- 2004-12-06 US US11/005,446 patent/US20070060504A1/en not_active Abandoned
- 2004-12-06 US US11/005,471 patent/US20070042990A1/en not_active Abandoned
- 2004-12-06 US US11/005,466 patent/US20070060541A1/en not_active Abandoned
- 2004-12-06 US US11/005,440 patent/US20070060503A1/en not_active Abandoned
- 2004-12-06 US US11/005,442 patent/US20070037735A1/en not_active Abandoned
- 2004-12-06 US US11/005,444 patent/US7625875B2/en not_active Expired - Fee Related
-
2005
- 2005-01-25 MA MA28070A patent/MA27374A1/fr unknown
- 2005-01-27 NO NO20050490A patent/NO20050490L/no not_active Application Discontinuation
-
2014
- 2014-08-07 LU LU92513C patent/LU92513I2/fr unknown
Also Published As
Publication number | Publication date |
---|---|
US7625875B2 (en) | 2009-12-01 |
US20040077587A1 (en) | 2004-04-22 |
EP1536804A2 (fr) | 2005-06-08 |
US20070015905A1 (en) | 2007-01-18 |
US20070060505A1 (en) | 2007-03-15 |
US7662798B2 (en) | 2010-02-16 |
RS113904A (en) | 2007-02-05 |
US20070060503A1 (en) | 2007-03-15 |
EP1536804A4 (fr) | 2007-10-31 |
US20070042990A1 (en) | 2007-02-22 |
KR20050035194A (ko) | 2005-04-15 |
PL374781A1 (en) | 2005-10-31 |
MA27374A1 (fr) | 2005-06-01 |
AP2005003213A0 (en) | 2005-03-31 |
JP2005533824A (ja) | 2005-11-10 |
BR0312278A (pt) | 2007-06-19 |
AU2003248748A1 (en) | 2004-01-19 |
NO20050490L (no) | 2005-01-27 |
WO2004002422A3 (fr) | 2005-04-07 |
US20070060504A1 (en) | 2007-03-15 |
WO2004002422A2 (fr) | 2004-01-08 |
US20070060541A1 (en) | 2007-03-15 |
CA2489552A1 (fr) | 2004-01-08 |
US20070060498A1 (en) | 2007-03-15 |
MXPA04012802A (es) | 2005-04-19 |
US7456155B2 (en) | 2008-11-25 |
US20070037735A1 (en) | 2007-02-15 |
CN1678326A (zh) | 2005-10-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
LU92513I2 (fr) | Sofosbuvir et ses dérivés pharmaceutiquement acceptables (solvaldi) | |
LU92517I2 (fr) | Delamanide et ses dérivés pharmaceutiquement acceptables | |
LU92419I2 (fr) | Riociguat et ses dérivés pharmaceutiquement acceptables (ADEMPAS®) | |
LU92381I2 (fr) | Macitentan et ses dérivés pharmaceutiquement acceptables (OPSUMIT) | |
LU93093I2 (fr) | Nécitumumab et ses dérivés pharmaceutiquement acceptables (portrazza) | |
LU92336I2 (fr) | Trastuzumab emtansine et ses dérivés pharmaceutiquement acceptables (KADCYLA) | |
LU93189I2 (fr) | Ixekizumab et ses dérivés pharmaceutiquement acceptables (TALTZ) | |
LU92024I2 (fr) | Pasireotide et ses dérivés pharmaceutiquement acceptables (SIGNIFOR) | |
LU92871I2 (fr) | Fumarate de diméthyle et ses dérivés pharmaceutiquement acceptables (tecfidera) | |
LU91757I2 (fr) | Denosumab et ses dérivés pharmaceutiquement acceptables (PROLIA®) | |
LUC00127I1 (fr) | Dacomitinib et ses derives pharmaceutiquement accepatbles ( vizimpro ) | |
LU91883I2 (fr) | Pradofloxacin et ses dérivés pharmaceutiquement acceptables (VERAFLOX®) | |
IS2599B (is) | 3-fenýlsúlfónýl-8-píperasín-1-ýl-kínólín og lyfjafræðilega viðurkenndar afleiður þess | |
LU92326I2 (fr) | Canakinumab et ses dérivés pharmaceutiquement acceptables (ILARIS) | |
LU92182I2 (fr) | Dapagliflozine et ses sels pharmaceutiquement acceptables | |
LU92745I2 (fr) | Nétupitant/Palonosétron et leurs dérivés pharmaceutiquement acceptables (AKYNZEOr) | |
LU92634I2 (fr) | Flutémétamol (18f) et ses dérivés pharmaceutiquement acceptables (vizamyl) | |
LU91269I2 (fr) | Rotigotine et ses dérivés pharmaceutiquement acceptables (neupro) | |
LU91655I2 (fr) | Corifollitropine alfa et ses dérivés pharmaceutiquement acceptables (ELONVA®) | |
IS7948A (is) | Fosfónóoxýkínasólínafleiður og lyfjafræileg notkun þeirra | |
DE60324099D1 (de) | Arzneistoffhaltiger tampon | |
IS7872A (is) | Pýrrólópýrimidín afleiður | |
ATE478870T1 (de) | Spiroindolinpiperidinderivate | |
ATE460418T1 (de) | Heterocyclocarboxamidderivate | |
ATE450506T1 (de) | Indol-3-schwefelderivate |